Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TScan Therapeutics, Inc. (TCRX) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. TScan is a clinical-stage biotechnology company listed on The Nasdaq Global Market, and its filings offer detailed insight into its T cell receptor-engineered T cell (TCR-T) therapy programs, financial condition, and corporate governance.
For TCRX, key filings include current reports on Form 8-K that describe material events such as clinical and regulatory milestones for TSC-101 in the ALLOHA™ Phase 1 heme trial, strategic prioritization of the hematologic malignancies program, pauses in solid tumor trial enrollment, and updates on in vivo engineering and autoimmunity research. Other 8-Ks address financial results, workforce changes, executive appointments, and stockholder meeting outcomes. These documents help readers understand how TScan is advancing its heme and solid tumor programs, implementing a commercial-ready manufacturing process, and managing its operating runway.
Investors can also use this page to locate annual and quarterly reports (Forms 10-K and 10-Q) when available, which typically contain comprehensive discussions of TScan’s pipeline, risk factors, and financial statements. In addition, filings related to equity compensation plans, retention programs for key executives, and stockholder votes provide visibility into compensation structures and governance practices.
Stock Titan enhances access to TCRX filings by offering real-time updates from EDGAR and AI-powered summaries that explain the significance of each document in straightforward language. Users can quickly scan for information on clinical trial plans, cash runway disclosures, strategic shifts between heme, solid tumor, and autoimmunity efforts, and other developments that shape TScan Therapeutics’ profile as a public biotechnology company.